Amgen’s interchangeable Soliris biosimilar Bkemv approved by FDA for rare blood disorders
Amgen’s Bkemv (eculizumab-aeeb) has been approved by the US Food and Drug Administration (FDA) as the first interchangeable biosimilar to AstraZeneca’s Soliris (eculizumab) for two rare diseases characterised by the breakdown of red blood cells. The …